Page last updated: 2024-10-20

selenic acid and Supranuclear Palsy, Progressive

selenic acid has been researched along with Supranuclear Palsy, Progressive in 1 studies

Selenic Acid: A strong dibasic acid with the molecular formula H2SeO4. Included under this heading is the acid form, and inorganic salts of dihydrogen selenium tetraoxide.

Supranuclear Palsy, Progressive: A degenerative disease of the central nervous system characterized by balance difficulties; OCULAR MOTILITY DISORDERS (supranuclear ophthalmoplegia); DYSARTHRIA; swallowing difficulties; and axial DYSTONIA. Onset is usually in the fifth decade and disease progression occurs over several years. Pathologic findings include neurofibrillary degeneration and neuronal loss in the dorsal MESENCEPHALON; SUBTHALAMIC NUCLEUS; RED NUCLEUS; pallidum; dentate nucleus; and vestibular nuclei. (From Adams et al., Principles of Neurology, 6th ed, pp1076-7)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Vivash, L1
Bertram, KL1
Malpas, CB1
Marotta, C1
Harding, IH1
Kolbe, S1
Fielding, J1
Clough, M1
Lewis, SJG1
Tisch, S1
Evans, AH1
O'Sullivan, JD1
Kimber, T1
Darby, D1
Churilov, L1
Law, M1
Hovens, CM1
Velakoulis, D1
O'Brien, TJ1

Trials

1 trial available for selenic acid and Supranuclear Palsy, Progressive

ArticleYear
Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: protocol for a phase 2, randomised, double-blind, placebo-controlled trial.
    BMJ open, 2021, 12-16, Volume: 11, Issue:12

    Topics: Australia; Clinical Trials, Phase II as Topic; Double-Blind Method; Humans; Randomized Controlled Tr

2021